Momentum score · price trend
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,874 stocks |
|---|---|---|
| Last 12 months | +69.9% | 88% |
| Last 6 months | +63.5% | 83% |
| Last 3 months | +57.1% | 96% |
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,874 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Fermenta Biotech Ltd: 0.4 × 88 + 0.4 × 83 + 0.2 × 96 = 88.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 1 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Fermenta Biotech Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 105 | 82 | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 | 130 | 137 | 122 |
| Expenses + | 86 | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 | 104 | 112 | 102 |
| Operating Profit | 19 | 11 | -14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 | 27 | 25 | 20 |
| OPM % | 18% | 13% | -24% | 25% | 6% | 1% | 20% | 34% | 26% | 21% | 20% | 18% | 16% |
| Other Income + | -8 | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 | 5 | 1 | 14 |
| Interest | 6 | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| Depreciation | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 |
| Profit before tax | -1 | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 | 24 | 17 | 26 |
| Tax % | 373% | 0% | 0% | 38% | 885% | 0% | 6% | 16% | -4% | 23% | 25% | 31% | 29% |
| Net Profit + | -5 | 2 | -29 | 10 | -7 | -6 | 11 | 38 | 33 | 22 | 18 | 12 | 19 |
| EPS in Rs | -1.40 | 0.62 | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.14 | 4.31 | 6.52 |
Financials of Fermenta Biotech Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 525 |
| Expenses + | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 426 |
| Operating Profit | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 100 |
| OPM % | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 19% |
| Other Income + | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 29 |
| Interest | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 12 |
| Depreciation | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 22 |
| Profit before tax | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 96 |
| Tax % | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | 27% |
| Net Profit + | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 70 |
| EPS in Rs | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 24.39 |
| Dividend Payout % | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% | 15% |
Financials of Fermenta Biotech Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 14 |
| Reserves | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 392 |
| Borrowings + | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 113 |
| Other Liabilities + | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 128 |
| Total Liabilities | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
| Fixed Assets + | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 220 |
| CWIP | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 |
| Investments | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets + | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 414 |
| Total Assets | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
Financials of Fermenta Biotech Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 | 93 |
| Cash from Investing Activity + | -18 | -13 | 7 | -101 | -97 | -44 | -41 | -26 | -55 | -16 | -0 | -43 |
| Cash from Financing Activity + | 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | -41 | -91 | -51 | -42 |
| Net Cash Flow | -2 | 1 | -4 | 47 | 6 | -57 | 21 | -4 | 19 | -1 | -10 | 8 |
| Free Cash Flow | -20 | -25 | -17 | 42 | 55 | -34 | 7 | 6 | 76 | 86 | 38 | 63 |
| CFO/OP | 119% | 35% | 35% | 83% | 79% | 73% | 92% | 85% | 610% | 370% | 38% | 109% |
Financials of Fermenta Biotech Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 | 78 |
| Inventory Days | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 | 290 |
| Days Payable | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 | 147 |
| Cash Conversion Cycle | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 189 | 221 |
| Working Capital Days | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 | 96 |
| ROCE % | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% | 20% |
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.